Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 3;9(2):119.
doi: 10.3390/vaccines9020119.

COVID-19 Vaccine Acceptance among Health Care Workers in the United States

Rahul Shekhar  1 , Abu Baker Sheikh  1 , Shubhra Upadhyay  1 , Mriganka Singh  2 , Saket Kottewar  3 , Hamza Mir  4 , Eileen Barrett  1 , Suman Pal  1
Affiliations

COVID-19 Vaccine Acceptance among Health Care Workers in the United States

Rahul Shekhar et al. Vaccines (Basel). .

Abstract

Background: Acceptance of the COVID-19 vaccine will play a major role in combating the pandemic. Healthcare workers (HCWs) are among the first group to receive vaccination, so it is important to consider their attitudes about COVID-19 vaccination to better address barriers to widespread vaccination acceptance.

Methods: We conducted a cross sectional study to assess the attitude of HCWs toward COVID-19 vaccination. Data were collected between 7 October and 9 November 2020. We received 4080 responses out of which 3479 were complete responses and were included in the final analysis.

Results: 36% of respondents were willing to take the vaccine as soon as it became available while 56% were not sure or would wait to review more data. Only 8% of HCWs do not plan to get vaccine. Vaccine acceptance increased with increasing age, education, and income level. A smaller percentage of female (31%), Black (19%), Lantinx (30%), and rural (26%) HCWs were willing to take the vaccine as soon as it became available than the overall study population. Direct medical care providers had higher vaccine acceptance (49%). Safety (69%), effectiveness (69%), and speed of development/approval (74%) were noted as the most common concerns regarding COVID-19 vaccination in our survey.

Keywords: Covid-19; United States; healthcare workers; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Attitude of healthcare workers toward vaccines.
See this image and copyright information in PMC

References

    1. Johns Hopkins Coronavirus Resource Center Global Map. [(accessed on 6 October 2020)]; Available online: https://coronavirus.jhu.edu/map.html.
    1. Adaptive Phase IB-II Randomized Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Loaded with Antigens from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), with or without GM-CSF, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies. ClinicalTrials.gov identifier (NCT number): NCT04386252. [(accessed on 11 December 2020)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04386252.
    1. A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older. ClinicalTrials.gov Identifier: NCT04505722. [(accessed on 11 December 2020)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04505722.
    1. A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older. ClinicalTrials.gov Identifier: NCT04405076. [(accessed on 11 December 2020)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04405076.
    1. A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants. ClinicalTrials.gov Identifier: NCT04498247. [(accessed on 11 December 2020)]; Available online: https://www.clinicaltrials.gov/ct2/show/NCT04498247.

LinkOut - more resources